♥

AstraZeneca Pharma India Limited

ISIN : INE203A01020
NSE : ASTRAZEN
BSE : 506820
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 64.60
EPS (TTM) : 38.34
Price to Earning (P/E) : 133.25
Book Value : 283.45
Price to Bookvalue (P/B) : 30.37
Dividend Yield : 0 %
Return on Equity (ROE) : 24.95 %
Return on Capital Employed (ROCE) : 33.94 %

AstraZeneca Pharma share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	7852.5 - 7817.7 -0.4 %
Low / High	7700 - 7860.5 2.1 %
Trade Volume	466
52 Week Low / High	7685 - 10653.05 38.6 %

YOU MAY ALSO LIKE

High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms
Stock market course tutorial
Stock Market Investment Course explained in simple words.
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	2319.63	2323.32	2361.27	2498.09	2847.03	2954.67	3110.72	3057.89	3831.99	3875.2
Total Income	2356.47	2364.46	2429.21	2570.05	2927.01	3035.71	3194.44	3154.49	3919.29	3958.7
Total Expenditure	1940.02	2043.68	1954.01	2132.2	2248.55	2282.22	2583.12	2907.33	3338.11	3494.5
Other Income	36.84	41.14	67.94	71.96	79.97	81.04	83.73	96.6	87.3	83.5
Operating Profit	416.45	320.78	475.2	437.85	678.46	753.49	611.32	247.16	581.18	464.2
Interest	2.07	1.86	1.62	1.97	0.88	1.54	5	6.13		1.1
Exceptional Items					-402.29		164.26			-575.6
PBDT	414.38	318.92	473.58	435.88	275.29	751.95	770.58	241.03	581.18	-112.5
Depreciation	44.07	45.92	32.87	41.32	42.49	37.98	36.74	37.05	37.64	39.1
Profit Before Tax	370.31	273	440.71	394.56	232.8	713.97	733.84	203.98	543.54	-151.6
Tax	90.47	71.45	115.05	101.52	60.09	175.37	210.15	45.98	148.76	-33.7
Profit After Tax	279.84	201.55	325.66	293.04	172.71	538.6	523.69	158	394.78	-117.9
Net Profit	279.84	201.55	325.66	293.04	172.71	538.6	523.69	158	394.78	-117.9
Equity Capital	50	50	50	50	50	50	50	50	50	50
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72
Diluted Eps After Extraordinary Items	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72
Diluted Eps Before Extraordinary Items	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72

STANDALONE QUARTERLY RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	2319.63	2323.32	2361.27	2498.09	2847.03	2954.67	3110.72	3057.89	3831.99	3875.2
Total Income	2356.47	2364.46	2429.21	2570.05	2927.01	3035.71	3194.44	3154.49	3919.29	3958.7
Total Expenditure	1940.02	2043.68	1954.01	2132.2	2248.55	2282.22	2583.12	2907.33	3338.11	3494.5
Other Income	36.84	41.14	67.94	71.96	79.97	81.04	83.73	96.6	87.3	83.5
Operating Profit	416.45	320.78	475.2	437.85	678.46	753.49	611.32	247.16	581.18	464.2
Interest	2.07	1.86	1.62	1.97	0.88	1.54	5	6.13		1.1
Exceptional Items					-402.29		164.26			-575.6
PBDT	414.38	318.92	473.58	435.88	275.29	751.95	770.58	241.03	581.18	-112.5
Depreciation	44.07	45.92	32.87	41.32	42.49	37.98	36.74	37.05	37.64	39.1
Profit Before Tax	370.31	273	440.71	394.56	232.8	713.97	733.84	203.98	543.54	-151.6
Tax	90.47	71.45	115.05	101.52	60.09	175.37	210.15	45.98	148.76	-33.7
Profit After Tax	279.84	201.55	325.66	293.04	172.71	538.6	523.69	158	394.78	-117.9
Net Profit	279.84	201.55	325.66	293.04	172.71	538.6	523.69	158	394.78	-117.9
Equity Capital	50	50	50	50	50	50	50	50	50	50
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72
Diluted Eps After Extraordinary Items	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72
Diluted Eps Before Extraordinary Items	11.19	8.06	13.03	11.72	6.91	21.54	20.95	6.32	15.79	-4.72

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	8056	10029.7	12955.3
Total Income	8203.58	10290.7	13303.3
Total Expenditure	7194.25	8376.46	11110.8
Other Income	147.58	261.02	348
Operating Profit	1009.33	1914.27	2192.52
Interest	9.47	8.33	12.01
Exceptional Items		-402.29	164.26
PBDT	999.86	1503.65	2344.77
Depreciation	169.49	162.6	149.4
Profit Before Tax	830.37	1341.05	2195.37
Tax	214.43	348.12	580.28
Profit After Tax	615.94	992.93	1615.09
Net Profit	615.94	992.93	1615.09
Equity Capital	50	50	50
Face Value (IN RS)	2	2	2
Reserves	5063.93	5836.88	7069.17
Calculated EPS	24.64	39.72	64.6
Diluted Eps After Extraordinary Items	24.64	39.72	64.6
Diluted Eps Before Extraordinary Items	24.64	39.72	64.6

STANDALONE ANNUAL RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	8056	10029.7	12955.3
Total Income	8203.58	10290.7	13303.3
Total Expenditure	7194.25	8376.46	11110.8
Other Income	147.58	261.02	348
Operating Profit	1009.33	1914.27	2192.52
Interest	9.47	8.33	12.01
Exceptional Items		-402.29	164.26
PBDT	999.86	1503.65	2344.77
Depreciation	169.49	162.6	149.4
Profit Before Tax	830.37	1341.05	2195.37
Tax	214.43	348.12	580.28
Profit After Tax	615.94	992.93	1615.09
Net Profit	615.94	992.93	1615.09
Equity Capital	50	50	50
Face Value (IN RS)	2	2	2
Reserves	5063.93	5836.88	7069.17
Calculated EPS	24.64	39.72	64.6
Diluted Eps After Extraordinary Items	24.64	39.72	64.6
Diluted Eps Before Extraordinary Items	24.64	39.72	64.6

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR ASTRAZENECA PHARMA INDIA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	813.56 Cr	809.45 Cr	1007.61 Cr	1302.14 Cr
Sales	776.79 Cr	765.27 Cr	946.39 Cr	1212.25 Cr
Processing Charges / Service Income	31.77 Cr	44.18 Cr	61.22 Cr	89.89 Cr
Net Sales	813.56 Cr	805.6 Cr	1002.97 Cr	1295.53 Cr
Increase/Decrease in Stock	2.95 Cr	14.47 Cr	-48.86 Cr	-33.77 Cr
Raw Material Consumed	284.35 Cr	290.81 Cr	404.08 Cr	623.8 Cr
Opening Raw Materials	20.63 Cr	20 Cr	15.28 Cr	14.92 Cr
Purchases Raw Materials	88.98 Cr	76.72 Cr	79.26 Cr	127.61 Cr
Closing Raw Materials	20 Cr	13.79 Cr	14.92 Cr	18.04 Cr
Other Direct Purchases / Brought in cost	194.74 Cr	207.88 Cr	324.46 Cr	499.31 Cr
Power & Fuel Cost	7.37 Cr	8.1 Cr	5.54 Cr	4.87 Cr
Electricity & Power	7.37 Cr	8.1 Cr	5.54 Cr	4.87 Cr
Employee Cost	219.54 Cr	230.21 Cr	259.1 Cr	241.45 Cr
Salaries, Wages & Bonus	191.75 Cr	199.21 Cr	225.23 Cr	203.74 Cr
Contributions to EPF & Pension Funds	10.55 Cr	11.48 Cr	10.91 Cr	10.37 Cr
Workmen and Staff Welfare Expenses	11.37 Cr	13.03 Cr	15.81 Cr	20.32 Cr
Other Manufacturing Expenses	49.32 Cr	57.12 Cr	76.04 Cr	89.46 Cr
Repairs and Maintenance	6.08 Cr	4.94 Cr	6 Cr	6.23 Cr
Packing Material Consumed	7.65 Cr	6.68 Cr	4.76 Cr	4.53 Cr
General and Administration Expenses	40.69 Cr	40.04 Cr	56.66 Cr	66.3 Cr
Rent , Rates & Taxes	3.02 Cr	2.01 Cr	2.35 Cr	3.22 Cr
Insurance	3.04 Cr	2.7 Cr	2.95 Cr	3.87 Cr
Professional and legal fees	23.54 Cr	21.48 Cr	23.39 Cr	34.68 Cr
Traveling and conveyance	5.78 Cr	10.03 Cr	24.38 Cr	20.93 Cr
Selling and Distribution Expenses	55.94 Cr	62.09 Cr	71.57 Cr	97.48 Cr
Sales Commissions & Incentives	4.74 Cr	5.1 Cr	5.35 Cr	0
Freight and Forwarding	5.99 Cr	6.27 Cr	6.48 Cr	11.47 Cr
Miscellaneous Expenses	17.93 Cr	16.58 Cr	13.72 Cr	21.49 Cr
Bad debts /advances written off	0	29 Lk	3 Lk	0
Provision for doubtful debts	2.72 Cr	4 Cr	1.67 Cr	5.44 Cr
Loss on foreign exchange fluctuations	54 Lk	13 Lk	0	50 Lk
Total Expenditure	678.09 Cr	719.42 Cr	837.85 Cr	1111.08 Cr
Other Income	12.84 Cr	14.76 Cr	26.1 Cr	34.8 Cr
Interest Received	10.46 Cr	11.48 Cr	23.12 Cr	32.57 Cr
Profit on sale of Fixed Assets	2.17 Cr	2.82 Cr	2.49 Cr	3 Lk
Provision Written Back	0	0	0	18 Lk
Foreign Exchange Gains	0	0	28 Lk	0
Operating Profit	148.31 Cr	100.94 Cr	191.22 Cr	219.25 Cr
Interest	1.09 Cr	95 Lk	63 Lk	1.2 Cr
PBDT	147.22 Cr	99.99 Cr	190.59 Cr	218.05 Cr
Depreciation	20.13 Cr	16.95 Cr	16.26 Cr	14.94 Cr
Profit Before Taxation & Exceptional Items	127.09 Cr	83.04 Cr	174.33 Cr	203.11 Cr
Exceptional Income / Expenses	0	0	-40.23 Cr	16.43 Cr
Profit Before Tax	127.09 Cr	83.04 Cr	134.1 Cr	219.54 Cr
Provision for Tax	33.79 Cr	21.44 Cr	34.81 Cr	58.03 Cr
Current Income Tax	0	22.63 Cr	38.3 Cr	53.55 Cr
Deferred Tax	-1.04 Cr	-1.19 Cr	-3.49 Cr	-90 Lk
Profit After Tax	93.3 Cr	61.6 Cr	99.29 Cr	161.51 Cr
Consolidated Net Profit	93.3 Cr	61.6 Cr	99.29 Cr	161.51 Cr
Profit Balance B/F	232.37 Cr	324.1 Cr	378.96 Cr	455.64 Cr
Appropriations	325.67 Cr	385.7 Cr	478.25 Cr	617.15 Cr
Other Appropriation	-3.43 Cr	1.74 Cr	22.61 Cr	39 Cr
Equity Dividend %	100	500	800	1200
Earnings Per Share	37.32	24.64	39.72	64.6
Adjusted EPS	37.32	24.64	39.72	64.6

STANDALONE PROFIT / LOSS FOR ASTRAZENECA PHARMA INDIA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	813.56 Cr	809.45 Cr	1007.61 Cr	1302.14 Cr
Sales	776.79 Cr	765.27 Cr	946.39 Cr	1212.25 Cr
Processing Charges / Service Income	31.77 Cr	44.18 Cr	61.22 Cr	89.89 Cr
Net Sales	813.56 Cr	805.6 Cr	1002.97 Cr	1295.53 Cr
Increase/Decrease in Stock	2.95 Cr	14.47 Cr	-48.86 Cr	-33.77 Cr
Raw Material Consumed	284.35 Cr	290.81 Cr	404.08 Cr	623.8 Cr
Opening Raw Materials	20.63 Cr	20 Cr	15.28 Cr	14.92 Cr
Purchases Raw Materials	88.98 Cr	76.72 Cr	79.26 Cr	127.61 Cr
Closing Raw Materials	20 Cr	13.79 Cr	14.92 Cr	18.04 Cr
Other Direct Purchases / Brought in cost	194.74 Cr	207.88 Cr	324.46 Cr	499.31 Cr
Power & Fuel Cost	7.37 Cr	8.1 Cr	5.54 Cr	4.87 Cr
Electricity & Power	7.37 Cr	8.1 Cr	5.54 Cr	4.87 Cr
Employee Cost	219.54 Cr	230.21 Cr	259.1 Cr	241.45 Cr
Salaries, Wages & Bonus	191.75 Cr	199.21 Cr	225.23 Cr	203.74 Cr
Contributions to EPF & Pension Funds	10.55 Cr	11.48 Cr	10.91 Cr	10.37 Cr
Workmen and Staff Welfare Expenses	11.37 Cr	13.03 Cr	15.81 Cr	20.32 Cr
Other Manufacturing Expenses	49.32 Cr	57.12 Cr	76.04 Cr	89.46 Cr
Repairs and Maintenance	6.08 Cr	4.94 Cr	6 Cr	6.23 Cr
Packing Material Consumed	7.65 Cr	6.68 Cr	4.76 Cr	4.53 Cr
General and Administration Expenses	40.69 Cr	40.04 Cr	56.66 Cr	66.3 Cr
Rent , Rates & Taxes	3.02 Cr	2.01 Cr	2.35 Cr	3.22 Cr
Insurance	3.04 Cr	2.7 Cr	2.95 Cr	3.87 Cr
Professional and legal fees	23.54 Cr	21.48 Cr	23.39 Cr	34.68 Cr
Traveling and conveyance	5.78 Cr	10.03 Cr	24.38 Cr	20.93 Cr
Selling and Distribution Expenses	55.94 Cr	62.09 Cr	71.57 Cr	97.48 Cr
Sales Commissions & Incentives	4.74 Cr	5.1 Cr	5.35 Cr	0
Freight and Forwarding	5.99 Cr	6.27 Cr	6.48 Cr	11.47 Cr
Miscellaneous Expenses	17.93 Cr	16.58 Cr	13.72 Cr	21.49 Cr
Bad debts /advances written off	0	29 Lk	3 Lk	0
Provision for doubtful debts	2.72 Cr	4 Cr	1.67 Cr	5.44 Cr
Loss on foreign exchange fluctuations	54 Lk	13 Lk	0	50 Lk
Total Expenditure	678.09 Cr	719.42 Cr	837.85 Cr	1111.08 Cr
Other Income	12.84 Cr	14.76 Cr	26.1 Cr	34.8 Cr
Interest Received	10.46 Cr	11.48 Cr	23.12 Cr	32.57 Cr
Profit on sale of Fixed Assets	2.17 Cr	2.82 Cr	2.49 Cr	3 Lk
Provision Written Back	0	0	0	18 Lk
Foreign Exchange Gains	0	0	28 Lk	0
Operating Profit	148.31 Cr	100.94 Cr	191.22 Cr	219.25 Cr
Interest	1.09 Cr	95 Lk	63 Lk	1.2 Cr
PBDT	147.22 Cr	99.99 Cr	190.59 Cr	218.05 Cr
Depreciation	20.13 Cr	16.95 Cr	16.26 Cr	14.94 Cr
Profit Before Taxation & Exceptional Items	127.09 Cr	83.04 Cr	174.33 Cr	203.11 Cr
Exceptional Income / Expenses	0	0	-40.23 Cr	16.43 Cr
Profit Before Tax	127.09 Cr	83.04 Cr	134.1 Cr	219.54 Cr
Provision for Tax	33.79 Cr	21.44 Cr	34.81 Cr	58.03 Cr
Current Income Tax	0	22.63 Cr	38.3 Cr	53.55 Cr
Deferred Tax	-1.04 Cr	-1.19 Cr	-3.49 Cr	-90 Lk
Profit After Tax	93.3 Cr	61.6 Cr	99.29 Cr	161.51 Cr
Consolidated Net Profit	93.3 Cr	61.6 Cr	99.29 Cr	161.51 Cr
Profit Balance B/F	232.37 Cr	324.1 Cr	378.96 Cr	455.64 Cr
Appropriations	325.67 Cr	385.7 Cr	478.25 Cr	617.15 Cr
Other Appropriation	-3.43 Cr	1.74 Cr	22.61 Cr	39 Cr
Equity Dividend %	100	500	800	1200
Earnings Per Share	37.32	24.64	39.72	64.6
Adjusted EPS	37.32	24.64	39.72	64.6

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR ASTRAZENECA PHARMA INDIA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	127.09 Cr	83.04 Cr	134.1 Cr	219.54 Cr
Adjustment	14.2 Cr	9.66 Cr	-4.8 Cr	-7.07 Cr
Changes In working Capital	-3.95 Cr	32.89 Cr	-30.19 Cr	-128.17 Cr
Cash Flow after changes in Working Capital	137.34 Cr	125.59 Cr	99.11 Cr	84.3 Cr
Cash Flow from Operating Activities	104.78 Cr	100.8 Cr	58.29 Cr	27.87 Cr
Cash Flow from Investing Activities	173.03 Cr	4.74 Cr	18.11 Cr	21.74 Cr
Cash Flow from Financing Activitie	-8.97 Cr	-9.46 Cr	-24.48 Cr	-44.38 Cr
Net Cash Inflow / Outflow	268.84 Cr	96.08 Cr	51.92 Cr	5.23 Cr
Opening Cash & Cash Equivalents	83.5 Cr	352.34 Cr	448.42 Cr	500.34 Cr
Closing Cash & Cash Equivalent	352.34 Cr	448.42 Cr	500.34 Cr	505.57 Cr

STANDALONE CASH FLOW FOR ASTRAZENECA PHARMA INDIA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	127.09 Cr	83.04 Cr	134.1 Cr	219.54 Cr
Adjustment	14.2 Cr	9.66 Cr	-4.8 Cr	-7.07 Cr
Changes In working Capital	-3.95 Cr	32.89 Cr	-30.19 Cr	-128.17 Cr
Cash Flow after changes in Working Capital	137.34 Cr	125.59 Cr	99.11 Cr	84.3 Cr
Cash Flow from Operating Activities	104.78 Cr	100.8 Cr	58.29 Cr	27.87 Cr
Cash Flow from Investing Activities	173.03 Cr	4.74 Cr	18.11 Cr	21.74 Cr
Cash Flow from Financing Activitie	-8.97 Cr	-9.46 Cr	-24.48 Cr	-44.38 Cr
Net Cash Inflow / Outflow	268.84 Cr	96.08 Cr	51.92 Cr	5.23 Cr
Opening Cash & Cash Equivalents	83.5 Cr	352.34 Cr	448.42 Cr	500.34 Cr
Closing Cash & Cash Equivalent	352.34 Cr	448.42 Cr	500.34 Cr	505.57 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR ASTRAZENECA PHARMA INDIA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	5 Cr	5 Cr	5 Cr	5 Cr
Equity - Authorised	5 Cr	5 Cr	5 Cr	5 Cr
Equity - Issued	5 Cr	5 Cr	5 Cr	5 Cr
Equity Paid Up	5 Cr	5 Cr	5 Cr	5 Cr
Face Value	2	2	2	2
Total Reserves	449.58 Cr	504.44 Cr	581.12 Cr	703.63 Cr
Capital Reserves	72.35 Cr	72.35 Cr	72.35 Cr	72.35 Cr
Profit & Loss Account Balance	324.1 Cr	378.96 Cr	455.64 Cr	578.15 Cr
General Reserves	53.13 Cr	53.13 Cr	53.13 Cr	53.13 Cr
Reserve excluding Revaluation Reserve	449.58 Cr	504.44 Cr	581.12 Cr	703.63 Cr
Shareholder's Funds	456.17 Cr	511.39 Cr	588.69 Cr	711.92 Cr
Deferred Tax Assets / Liabilities	-14.53 Cr	-16.3 Cr	-20.67 Cr	-21.25 Cr
Deferred Tax Assets	17.31 Cr	18.17 Cr	22.2 Cr	22.31 Cr
Deferred Tax Liability	2.78 Cr	1.87 Cr	1.53 Cr	1.06 Cr
Other Long Term Liabilities	8.63 Cr	5.02 Cr	3.69 Cr	2.78 Cr
Long Term Provisions	50.5 Cr	84.91 Cr	85.97 Cr	116.3 Cr
Total Non-Current Liabilities	44.6 Cr	73.63 Cr	68.99 Cr	97.83 Cr
Trade Payables	178.37 Cr	188.06 Cr	227.88 Cr	196.51 Cr
Sundry Creditors	178.37 Cr	188.06 Cr	227.88 Cr	196.51 Cr
Other Current Liabilities	82.58 Cr	99.48 Cr	111.95 Cr	110.53 Cr
Short Term Provisions	112.48 Cr	104.76 Cr	144.57 Cr	160.11 Cr
Provision for Tax	79.81 Cr	68.84 Cr	107.14 Cr	120.76 Cr
Provision for post retirement benefits	1.01 Cr	1.17 Cr	63 Lk	1.06 Cr
Total Current Liabilities	373.43 Cr	392.3 Cr	484.4 Cr	467.15 Cr
Total Liabilities	874.2 Cr	977.32 Cr	1142.08 Cr	1276.9 Cr
Gross Block	159.78 Cr	168.83 Cr	179.12 Cr	187.13 Cr
Less: Accumulated Depreciation	78.82 Cr	94.34 Cr	110.26 Cr	120.45 Cr
Net Block	80.96 Cr	74.49 Cr	68.86 Cr	66.68 Cr
Capital Work in Progress	4.02 Cr	2.2 Cr	1.33 Cr	27 Lk
Long Term Loans & Advances	100.52 Cr	135.31 Cr	135.95 Cr	167.21 Cr
Other Non Current Assets	1 Lk	0	0	0
Total Non-Current Assets	185.51 Cr	212 Cr	206.14 Cr	234.16 Cr
Inventories	159.8 Cr	140.22 Cr	190.21 Cr	227.88 Cr
Raw Materials	20 Cr	13.79 Cr	14.92 Cr	18.04 Cr
Work-in Progress	3.74 Cr	3.06 Cr	1.67 Cr	4.73 Cr
Finished Goods	32.64 Cr	38.53 Cr	37.21 Cr	43.74 Cr
Packing Materials	2.14 Cr	1.76 Cr	1.51 Cr	1.34 Cr
Stores and Spare	1.78 Cr	1.77 Cr	1.72 Cr	1.74 Cr
Sundry Debtors	85.19 Cr	85.89 Cr	107.52 Cr	153.13 Cr
Debtors more than Six months	0	10.15 Cr	9.64 Cr	15.19 Cr
Debtors Others	96.28 Cr	90.83 Cr	114.64 Cr	160.14 Cr
Cash and Bank	352.35 Cr	448.46 Cr	500.48 Cr	505.84 Cr
Balances at Bank	352.35 Cr	448.46 Cr	500.48 Cr	505.84 Cr
Other Current Assets	14.05 Cr	23 Cr	13.56 Cr	13.23 Cr
Interest accrued on Investments	1.45 Cr	1.82 Cr	1.79 Cr	2.27 Cr
Prepaid Expenses	8.39 Cr	10.82 Cr	11.77 Cr	10.96 Cr
Short Term Loans and Advances	77.3 Cr	67.75 Cr	124.17 Cr	142.66 Cr
Advances recoverable in cash or in kind	55 Lk	1.27 Cr	65 Lk	1.01 Cr
Advance income tax and TDS	69.93 Cr	59.65 Cr	100.47 Cr	110.03 Cr
Total Current Assets	688.69 Cr	765.32 Cr	935.94 Cr	1042.74 Cr
Net Current Assets (Including Current Investments)	315.26 Cr	373.02 Cr	451.54 Cr	575.59 Cr
Total Assets	874.2 Cr	977.32 Cr	1142.08 Cr	1276.9 Cr
Contingent Liabilities	85.66 Cr	122.74 Cr	131.62 Cr	137.64 Cr
Book Value	181.83	203.78	234.45	283.45
Adjusted Book Value	181.83	203.78	234.45	283.45

STANDALONE BALANCE SHEET FOR ASTRAZENECA PHARMA INDIA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	5 Cr	5 Cr	5 Cr	5 Cr
Equity - Authorised	5 Cr	5 Cr	5 Cr	5 Cr
Equity - Issued	5 Cr	5 Cr	5 Cr	5 Cr
Equity Paid Up	5 Cr	5 Cr	5 Cr	5 Cr
Face Value	2	2	2	2
Total Reserves	449.58 Cr	504.44 Cr	581.12 Cr	703.63 Cr
Capital Reserves	72.35 Cr	72.35 Cr	72.35 Cr	72.35 Cr
Profit & Loss Account Balance	324.1 Cr	378.96 Cr	455.64 Cr	578.15 Cr
General Reserves	53.13 Cr	53.13 Cr	53.13 Cr	53.13 Cr
Reserve excluding Revaluation Reserve	449.58 Cr	504.44 Cr	581.12 Cr	703.63 Cr
Shareholder's Funds	456.17 Cr	511.39 Cr	588.69 Cr	711.92 Cr
Deferred Tax Assets / Liabilities	-14.53 Cr	-16.3 Cr	-20.67 Cr	-21.25 Cr
Deferred Tax Assets	17.31 Cr	18.17 Cr	22.2 Cr	22.31 Cr
Deferred Tax Liability	2.78 Cr	1.87 Cr	1.53 Cr	1.06 Cr
Other Long Term Liabilities	8.63 Cr	5.02 Cr	3.69 Cr	2.78 Cr
Long Term Provisions	50.5 Cr	84.91 Cr	85.97 Cr	116.3 Cr
Total Non-Current Liabilities	44.6 Cr	73.63 Cr	68.99 Cr	97.83 Cr
Trade Payables	178.37 Cr	188.06 Cr	227.88 Cr	196.51 Cr
Sundry Creditors	178.37 Cr	188.06 Cr	227.88 Cr	196.51 Cr
Other Current Liabilities	82.58 Cr	99.48 Cr	111.95 Cr	110.53 Cr
Short Term Provisions	112.48 Cr	104.76 Cr	144.57 Cr	160.11 Cr
Provision for Tax	79.81 Cr	68.84 Cr	107.14 Cr	120.76 Cr
Provision for post retirement benefits	1.01 Cr	1.17 Cr	63 Lk	1.06 Cr
Total Current Liabilities	373.43 Cr	392.3 Cr	484.4 Cr	467.15 Cr
Total Liabilities	874.2 Cr	977.32 Cr	1142.08 Cr	1276.9 Cr
Gross Block	159.78 Cr	168.83 Cr	179.12 Cr	187.13 Cr
Less: Accumulated Depreciation	78.82 Cr	94.34 Cr	110.26 Cr	120.45 Cr
Net Block	80.96 Cr	74.49 Cr	68.86 Cr	66.68 Cr
Capital Work in Progress	4.02 Cr	2.2 Cr	1.33 Cr	27 Lk
Long Term Loans & Advances	100.52 Cr	135.31 Cr	135.95 Cr	167.21 Cr
Other Non Current Assets	1 Lk	0	0	0
Total Non-Current Assets	185.51 Cr	212 Cr	206.14 Cr	234.16 Cr
Inventories	159.8 Cr	140.22 Cr	190.21 Cr	227.88 Cr
Raw Materials	20 Cr	13.79 Cr	14.92 Cr	18.04 Cr
Work-in Progress	3.74 Cr	3.06 Cr	1.67 Cr	4.73 Cr
Finished Goods	32.64 Cr	38.53 Cr	37.21 Cr	43.74 Cr
Packing Materials	2.14 Cr	1.76 Cr	1.51 Cr	1.34 Cr
Stores and Spare	1.78 Cr	1.77 Cr	1.72 Cr	1.74 Cr
Sundry Debtors	85.19 Cr	85.89 Cr	107.52 Cr	153.13 Cr
Debtors more than Six months	0	10.15 Cr	9.64 Cr	15.19 Cr
Debtors Others	96.28 Cr	90.83 Cr	114.64 Cr	160.14 Cr
Cash and Bank	352.35 Cr	448.46 Cr	500.48 Cr	505.84 Cr
Balances at Bank	352.35 Cr	448.46 Cr	500.48 Cr	505.84 Cr
Other Current Assets	14.05 Cr	23 Cr	13.56 Cr	13.23 Cr
Interest accrued on Investments	1.45 Cr	1.82 Cr	1.79 Cr	2.27 Cr
Prepaid Expenses	8.39 Cr	10.82 Cr	11.77 Cr	10.96 Cr
Short Term Loans and Advances	77.3 Cr	67.75 Cr	124.17 Cr	142.66 Cr
Advances recoverable in cash or in kind	55 Lk	1.27 Cr	65 Lk	1.01 Cr
Advance income tax and TDS	69.93 Cr	59.65 Cr	100.47 Cr	110.03 Cr
Total Current Assets	688.69 Cr	765.32 Cr	935.94 Cr	1042.74 Cr
Net Current Assets (Including Current Investments)	315.26 Cr	373.02 Cr	451.54 Cr	575.59 Cr
Total Assets	874.2 Cr	977.32 Cr	1142.08 Cr	1276.9 Cr
Contingent Liabilities	85.66 Cr	122.74 Cr	131.62 Cr	137.64 Cr
Book Value	181.83	203.78	234.45	283.45
Adjusted Book Value	181.83	203.78	234.45	283.45

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR ASTRAZENECA PHARMA INDIA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	37.32	24.64	39.72	64.6
CEPS(Rs)	45.37	31.42	46.22	70.58
DPS(Rs)	2	10	16	24
Book NAV/Share(Rs)	181.83	203.78	234.45	283.45
Tax Rate(%)	26.59	25.82	25.96	26.43
Margin Ratios
Core EBITDA Margin(%)	16.65	10.65	16.39	14.17
EBIT Margin(%)	15.76	10.38	13.37	16.95
Pre Tax Margin(%)	15.62	10.26	13.31	16.86
PAT Margin (%)	11.47	7.61	9.85	12.4
Cash Profit Margin (%)	13.94	9.7	11.47	13.55
Performance Ratios
ROA(%)	11.31	6.65	9.37	13.35
ROE(%)	22.83	12.78	18.13	24.95
ROCE(%)	31.24	17.36	24.49	33.94
Asset Turnover(x)	0.99	0.87	0.95	1.08
Sales/Fixed Asset(x)	5.56	4.93	5.79	7.11
Working Capital/Sales(x)	2.58	2.17	2.23	2.26
Efficiency Ratios
Fixed Capital/Sales(x)	0.18	0.2	0.17	0.14
Receivable days	37.78	38.57	35.03	36.53
Inventory Days	72.89	67.64	59.85	58.6
Payable days	111.16	219.06	214.92	131.27
Valuation Parameters
PER(x)	80.66	103.71	81.76	82.35
PCE(x)	66.34	81.33	70.26	75.38
Price/Book(x)	16.55	12.54	13.85	18.77
Yield(%)	0.07	0.39	0.49	0.45
EV/Net Sales(x)	8.82	7.37	7.6	9.88
EV/Core EBITDA(x)	48.37	58.85	39.84	58.36
EV/EBIT(x)	55.96	70.72	56.54	57.96
EV/CE(x)	8.21	6.08	6.67	17.97
M Cap / Sales	9.25	7.93	8.09	10.27
Growth Ratio
Net Sales Growth(%)	-2.19	-0.98	24.5	29.17
Core EBITDA Growth(%)	10.94	-31.94	89.44	14.66
EBIT Growth(%)	11.35	-34.48	60.41	63.84
PAT Growth(%)	29.21	-33.98	61.19	62.66
EPS Growth(%)	29.21	-33.98	61.19	62.66
Financial Stability Ratios
Current Ratio(x)	1.84	1.95	1.93	2.23
Quick Ratio(x)	1.42	1.59	1.54	1.74
Interest Cover(x)	117.6	88.41	213.86	183.95

FINANCIAL RATIOS (STANDALONE) FOR ASTRAZENECA PHARMA INDIA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	37.32	24.64	39.72	64.6
CEPS(Rs)	45.37	31.42	46.22	70.58
DPS(Rs)	2	10	16	24
Book NAV/Share(Rs)	181.83	203.78	234.45	283.45
Tax Rate(%)	26.59	25.82	25.96	26.43
Margin Ratios
Core EBITDA Margin(%)	16.65	10.65	16.39	14.17
EBIT Margin(%)	15.76	10.38	13.37	16.95
Pre Tax Margin(%)	15.62	10.26	13.31	16.86
PAT Margin (%)	11.47	7.61	9.85	12.4
Cash Profit Margin (%)	13.94	9.7	11.47	13.55
Performance Ratios
ROA(%)	11.31	6.65	9.37	13.35
ROE(%)	22.83	12.78	18.13	24.95
ROCE(%)	31.24	17.36	24.49	33.94
Asset Turnover(x)	0.99	0.87	0.95	1.08
Sales/Fixed Asset(x)	5.56	4.93	5.79	7.11
Working Capital/Sales(x)	2.58	2.17	2.23	2.26
Efficiency Ratios
Fixed Capital/Sales(x)	0.18	0.2	0.17	0.14
Receivable days	37.78	38.57	35.03	36.53
Inventory Days	72.89	67.64	59.85	58.6
Payable days	111.16	219.06	214.92	131.27
Valuation Parameters
PER(x)	80.66	103.71	81.76	82.35
PCE(x)	66.34	81.33	70.26	75.38
Price/Book(x)	16.55	12.54	13.85	18.77
Yield(%)	0.07	0.39	0.49	0.45
EV/Net Sales(x)	8.82	7.37	7.6	9.88
EV/Core EBITDA(x)	48.37	58.85	39.84	58.36
EV/EBIT(x)	55.96	70.72	56.54	57.96
EV/CE(x)	8.21	6.08	6.67	17.97
M Cap / Sales	9.25	7.93	8.09	10.27
Growth Ratio
Net Sales Growth(%)	-2.19	-0.98	24.5	29.17
Core EBITDA Growth(%)	10.94	-31.94	89.44	14.66
EBIT Growth(%)	11.35	-34.48	60.41	63.84
PAT Growth(%)	29.21	-33.98	61.19	62.66
EPS Growth(%)	29.21	-33.98	61.19	62.66
Financial Stability Ratios
Current Ratio(x)	1.84	1.95	1.93	2.23
Quick Ratio(x)	1.42	1.59	1.54	1.74
Interest Cover(x)	117.6	88.41	213.86	183.95

SHARE HOLDING PATTERN FOR ASTRAZENECA PHARMA INDIA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	75.00	0.00	0.00
FII %	2.48	2.49	2.61	2.70	2.68	2.69	2.66	2.73	2.79	2.90
DII %	0.20	0.20	0.20	0.19	0.15	0.00	0.01	0.02	0.02	0.03
Public %	21.22	21.18	20.97	20.89	20.41	19.90	19.58	18.49	17.21	17.01

PEER COMPARISON FOR ASTRAZENECA PHARMA INDIA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR ASTRAZENECA PHARMA

Exchange Date	Purpose	Book Closure Dates
BSE 25-Oct-2024	Board Meeting - Quarterly Results	13-Nov-2024
BSE 24-Jul-2024	Board Meeting - Quarterly Results	08-Aug-2024
BSE 27-May-2024	Dividend - Rs.24.0000 per share(1200%)Dividend
BSE 15-May-2024	Board Meeting - Dividend & Audited Results	27-May-2024
BSE 25-Jan-2024	Board Meeting - Quarterly Results	08-Feb-2024
BSE 30-Oct-2023	Board Meeting - Quarterly Results	09-Nov-2023
BSE 04-Aug-2023	Board Meeting - Quarterly Results	14-Aug-2023
BSE 30-May-2023	Dividend - Rs.16.0000 per share(800%)Dividend
BSE 23-May-2023	Board Meeting - Dividend & Audited Results	30-May-2023
BSE 30-Jan-2023	Board Meeting - Quarterly Results	10-Feb-2023
BSE 31-Oct-2022	Board Meeting - Quarterly Results	11-Nov-2022
BSE 01-Aug-2022	Board Meeting - Quarterly Results	08-Aug-2022
BSE 28-Jul-2022	AGM - Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the Noticeof the 43rd Annual General Meeting of the Company scheduled to be held on Monday, August 8, 2022 at 3.00 p.m. (IST) through Video Conferencing (VC)/ Other AudioVisual Means (OAVM). The Notice is being sent to the members of the Company throu...	08-Aug-2022
BSE 26-May-2022	Dividend - Rs.8.0000 per share(400%)Final Dividend
BSE 18-May-2022	Board Meeting - Final Dividend & Audited Results	26-May-2022
BSE 01-Feb-2022	Board Meeting - Quarterly Results	08-Feb-2022
BSE 02-Nov-2021	Board Meeting - Quarterly Results	09-Nov-2021

CORPORATE ANNOUNCEMENTS FOR ASTRAZENECA PHARMA

Exchange Date	Category File	Description
BSE 25-Oct-2024	Intimation FILE	Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Wednesday November 13 2024 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024.
BSE 25-Oct-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee the Board of Directors of the Company have approved the appointment of Ms. Amita Bhave as Director - Regulatory Affairs with effect from November 18 2024.
BSE 24-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations 2015 we would like to inform you that the RTA of the Company have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.
BSE 18-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations 2015 we would like to inform you that the have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.
BSE 15-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find the enclosed letter of the Company in relation to the captioned subject for your reference.
BSE 27-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of SEBI (LODR) Regulations 2015 we would like to inform you that the Registrar and Share Transfer Agents of the Company have informed the Company on the Loss of share certificate.
BSE 25-Sep-2024	Outcome FILE	Board Meeting Outcome for Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform the below:1. Based on the recommendation of the Nomination & Remuneration Committee meeting the Board of Directors have appointed Ms. Monica Widhani (DIN: 07674403) as an Additional Director (Independent) on the Board of the Company with effect from September 25 2024. 2. Mr. Narayan. K. Seshadri (DIN: 053563) Independent Director of the Company will retire as Director of the Company upon completion of his term of office at the close of business hours on September 29 2024.3. Ms. Shipla Divekar Nirula Independent Director has been unanimously elected as Chairperson of the Board. Please find enclosed the letter in this regard.
BSE 25-Sep-2024	General Announcements FILE	Increase In Volume This has reference to the email of BSE dated September 25 2024. We wish to inform that we have no information/announcement including pending announcement which in the Companys opinion may have a bearing on the price/volume behaviour in the scrip.
BSE 25-Sep-2024	General -	Clarification sought from AstraZeneca Pharma India Ltd The Exchange has sought clarification from AstraZeneca Pharma India Ltd on September 25 2024 with reference to Movement in Volume.The reply is awaited.
BSE 23-Sep-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 This is to inform that the Company has received permission for sale and distribution of Durvalumab 120mg/2.4 ml and 500mg/10 ml solution for infusion (Imfinzi) from the Central Drugs Standard Organisation for additional indication. The details of the same is mentioned in the attached letter.
BSE 20-Sep-2024	General Announcements FILE	Launch Of Tremelimumab (Imjudo) We refer to our earlier communication dated June 1 2023 intimating the receipt of Import and Market permission in Form CT-20 from Drugs Controller General of India for Tremelimumab (Imjudo) concentration for solution for infusion 20 mg/ml (25 mg/ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route. With regard to the same we wish to further update that the Company will launch Trmelimumab (Imjudo) in October 2024 in India.
BSE 20-Sep-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Please find enclosed the letter of the Company in relation to the captioned subject.
BSE 19-Sep-2024	General Announcements FILE	Launch Of Palivizumab (Synagis) We refer to our earlier communication dated September 30 2023 intimating the receipt of Import and Market Permission in Form CT-20 from Drugs Controller General of India for Palivizumab (Synagis) solution for injection 100mg/ml (r-DNA origin) (50mg/0.5mL & 100 mg/mL) presentations in single dose vials administered through intramuscular route). With regard to the same we wish to further update that the Company will launch Palivizumab (Synagis) in October 2024 in India.
BSE 13-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations 2015 we would like to inform you that the Registrar and Share Transfer Agents have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.
BSE 12-Sep-2024	Intimation FILE	Closure of Trading Window This is to inform you that in accordance with the provisions of SEBI (PIT) Regulations 2015 read with the Companys Code of Conduct for Prevention of Insider Trading the trading window for dealing in the Equity Shares of the Company will be closed from September 16 2024 and the same shall reopen after 48 hours from the declaration of un-audited financial results of the Company for the quarter ending September 30 2024.
BSE 12-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations 2015 we would like to inform you that the Registrar and Transfer Agents have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
BSE 09-Sep-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We are enclosing herewith the certificate dated September 4 2024 issued by Integrated Registry Management Services Private Limited Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018.
BSE 04-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations 2015 we would like to inform you that the Registrar and Share Transfer Agents of the Company have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
BSE 27-Aug-2024	General Announcements FILE	Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 we would like to inform that Dr. Anil Arjundas Kukreja currently the Vice-President - Medical Affairs and Regulatory at AstraZeneca Pharma India Limited has decided to pursue his career outside the organisation. He will complete his handover period by the close of business hours on September 30 2024. The Company is looking for a suitable replacement for the said position. We wish Dr. Anil Kukreja all the best in his future endeavours.
BSE 12-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Please find the enclosed copy of the newspaper publication of the unaudited financial results for the quarter ended June 30 2024.
BSE 09-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Please find the enclosed Voting Results and the Scrutinizers Report of 45th Annual General Meeting of the Company held on August 8 2024.
BSE 08-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Please find the enclosed document of the Company in relation to the summary of proceedings of the 45th Annual General Meeting of the Company.
BSE 08-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find the enclosed Press Release of the Company for the quarter ended June 30 2024.
BSE 08-Aug-2024	Outcome FILE	Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday August 8 2024 Please find the enclosed unaudited financial results for the quarter ended June 30 2024.
BSE 08-Aug-2024	Outcome FILE	Outcome Of The Board Meeting Held On Thursday August 8 2024 Please find the enclosed financial results for the quarter ended June 30 2024.
BSE 27-Jul-2024	General Announcements FILE	Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Please find the enclosed letter of the Company in relation to the captioned subject for your reference.
BSE 24-Jul-2024	Intimation FILE	Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday August 8 2024 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter ended June 30 2024.We would also like to inform you that the Trading Window remains closed for all Designated Persons from June 16 2024 to August 10 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.We request you to please take the same on record.
BSE 17-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Please find the enclosed Newspaper Publication for the Annual General Meeting of the Company to be held on Thursday August 8 2024 at 3:00 PM.
BSE 16-Jul-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations 2015 we would like to inform you that the RTA of the Company have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.
BSE 16-Jul-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Please find the enclosed Business Responsibility and Sustainability Report of the Company for the financial year 2023-24 which also forms part of the Annual Report for financial year 2023-24.

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Insider trading details found

BULK BLOCK DEALS FOR ASTRAZENECA PHARMA INDIA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 19-Sep-2022	Sell BLOCK	74,097 @ 3152.55	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	74,097 @ 3152.55	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	6,542 @ 3152.55	ISHARES INDIA SC MAURITIUS COMPANY
BSE 19-Sep-2022	Buy BLOCK	6,542 @ 3152.55	ISHARES MSCI INDIA SMALL-CAP ETF

DIVIDEND BY ASTRAZENECA PHARMA INDIA LIMITED

Ex Dividend Date	Dividend Type	Dividend
05-Jul-2024	DIVIDEND	24
14-Jul-2023	DIVIDEND	16
07-Jul-2022	DIVIDEND	8
18-Aug-2021	INTERIM DIVIDEND	2

SPLIT / BONUS BY ASTRAZENECA PHARMA INDIA LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

AstraZeneca Pharma India Limited

AstraZeneca Pharma share price

CONSOLIDATED QUARTERLY RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

STANDALONE QUARTERLY RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

CONSOLIDATED ANNUAL RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

STANDALONE ANNUAL RESULT FOR ASTRAZENECA PHARMA INDIA LIMITED

CONSOLIDATED PROFIT / LOSS FOR ASTRAZENECA PHARMA INDIA LIMITED

STANDALONE PROFIT / LOSS FOR ASTRAZENECA PHARMA INDIA LIMITED

CONSOLIDATED CASH FLOW FOR ASTRAZENECA PHARMA INDIA LIMITED

STANDALONE CASH FLOW FOR ASTRAZENECA PHARMA INDIA LIMITED

CONSOLIDATED BALANCE SHEET FOR ASTRAZENECA PHARMA INDIA LIMITED

STANDALONE BALANCE SHEET FOR ASTRAZENECA PHARMA INDIA LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR ASTRAZENECA PHARMA INDIA LIMITED

FINANCIAL RATIOS (STANDALONE) FOR ASTRAZENECA PHARMA INDIA LIMITED

SHARE HOLDING PATTERN FOR ASTRAZENECA PHARMA INDIA LIMITED

PEER COMPARISON FOR ASTRAZENECA PHARMA INDIA LIMITED

CORPORATE ACTIONS FOR ASTRAZENECA PHARMA

CORPORATE ANNOUNCEMENTS FOR ASTRAZENECA PHARMA

INSIDER TRADING FOR ASTRAZENECA PHARMA

BULK BLOCK DEALS FOR ASTRAZENECA PHARMA INDIA LIMITED

DIVIDEND BY ASTRAZENECA PHARMA INDIA LIMITED

SPLIT / BONUS BY ASTRAZENECA PHARMA INDIA LIMITED